Pooled across 34 studies data from 4.5+ million women showed that MHT use increased breast cancer odds by 15% versus non-use, ...
Clinical and payer strategies should treat GLP‑1 therapy as chronic for high-risk patients, addressing tolerability and cost ...
Pulmonary expert Noah Greenspan, DPT, discusses long COVID, early pandemic uncertainty, and how vaccination may help reduce ...
NHANES 2017–2018 elastography data (n=4102) linked to mortality showed 59 deaths over ~24 months; decedents were older and more likely to have diabetes. MASLD (CAP ≥274 dB/m) with diabetes carried ...
This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...
SEER-Medicare analyses across 2005–2007, 2010–2012, and 2017–2019 showed persistently lower adjusted curative-treatment rates ...
Humorous tone undermined engagement, whereas factual, straightforward framing aligned better with expectations for ...
Purposive-sampled Dutch interviews (n=23; median age 50; median MS duration 13 years) showed near-universal experience with ...
Fred D. Lublin, MD, discusses therapy sequencing, deescalation, health equity, and the future of multiple sclerosis (MS) care ...
Clonal hematopoiesis in chronic lymphocytic leukemia is widespread, shaping cytopenias, cardiovascular risk, and ...
FDA authorization covers moderate-to-severe plaque psoriasis in adults and patients aged ≥12 years, expanding systemic options for adolescents. Icotrokinra is characterized as a first-in-class ...
In Personalized Selection of Immunotherapy Strategies in Metastatic NSCLC and Future Evidence Gaps, our experts delve into ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results